Langone Eyes $2,000 for Eli Lilly in 3-4 Years

Ken Langone told CNBC that Eli Lilly (LLY) could reach $2,000 in three to four years, citing a $17-18B annual R&D budget and pipeline depth well beyond GLP-1s.

Lead

Home Depot (HD) co-founder and veteran investor Ken Langone appeared on CNBC Squawk Box on September 22, 2026, and named Eli Lilly (LLY) the closest investment parallel he has encountered to his original Home Depot bet, predicting the Indianapolis-based pharmaceutical company could reach $2,000 per share within three to four years. The target implies roughly 70% upside from LLY's Tuesday close of $1,153.83, adding approximately $900 billion in market capitalization to the company's current standing as one of the largest pharma companies in the world.

Why Does Langone See Such Upside in Eli Lilly Stock?

Langone grounds his thesis in the scale and diversification of Lilly's research budget, which he says has expanded from roughly $4 billion to $17-18 billion annually. He credited CEO David Ricks and Chief Scientific Officer Dan Skovronsky with broadening Lilly's ambitions well beyond its dominant GLP-1 franchise. "They're not relying completely on these weight loss drugs," Langone said. "They're building a fortress for activities in so many other different areas," adding that "the best is yet to come." His Lilly position has grown to rival his decades-old Home Depot stake in portfolio weight - a holding that transformed him into a billionaire over five decades.

Pipeline: What Lies Beyond GLP-1?

Lilly's commercial foundation currently rests on Mounjaro and Zepbound, its paired GLP-1/GIP receptor agonists that generated approximately $13 billion in first-quarter 2026 revenue and secured the company roughly 60% of the U.S. GLP-1 market. In 2026, Lilly added a new dimension to that franchise with FDA approval of Foundayo, an oral GLP-1 pill that has treated more than 20,000 patients since launch. Further along in development, retatrutide - a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously - could materially expand the addressable metabolic disease market.

Beyond metabolic disease, Lilly executed six major acquisitions in 2026. A $2.3 billion purchase of blood cancer specialist Ajax Therapeutics deepens its oncology platform, while the acquisition of 4E Therapeutics anchors an advanced non-opioid chronic pain pipeline. Active programs in Alzheimer's disease add further runway to a research portfolio that Langone describes as generating compounding returns across therapeutic categories rather than depending on any single drug class.

Financial Scale Supporting the Valuation Case

Lilly raised its full-year 2026 revenue guidance to $85 billion to $87 billion, supported by first-quarter 2026 revenue of $19.8 billion, a 55.5% year-over-year gain. Management also expanded its non-GAAP operating margin guidance by 2 percentage points over the same period. At $17-18 billion in annual R&D spending, Lilly is deploying capital at a pace that positions it to sustain multi-program pipeline output for years without reliance on a single therapeutic category - the structural characteristic Langone finds most reminiscent of Home Depot's multi-decade reinvestment cycle.

Is Langone's History With Lilly Unusual?

Langone's position in LLY stretches nearly five decades. He acquired control of IVAC, a San Diego medical device company, in 1972; Lilly purchased IVAC in 1977 for roughly $50 million in Lilly stock. He retained those shares and has added to the position through every major market drawdown since. The multi-decade holding horizon frames the $2,000 target not as a trading thesis but as a structural conviction about a platform company's capacity to compound capital allocation across successive generations of science.

Outlook

Eli Lilly enters the final quarter of 2026 with dominant GLP-1 market share, a validated oral delivery platform, a six-deal M&A program, and an R&D engine that has expanded materially into oncology, neurology, and pain. If revenue growth continues near its current pace and pipeline assets advance toward approval before 2030, the earnings power needed to support a $2,000 share price becomes increasingly concrete. Langone's comparison to his Home Depot experience suggests the most enduring returns in large-cap pharma investing tend to come from companies that consistently redeploy capital into new markets rather than defending a single franchise.